Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

@article{Whitcomb2003BroadNR,
  title={Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.},
  author={Jeannette M. Whitcomb and N. Parkin and Colombe Chappey and Nicholas S. Hellmann and Christos J. Petropoulos},
  journal={The Journal of infectious diseases},
  year={2003},
  volume={188 7},
  pages={992-1000}
}
Nucleoside reverse-transcriptase inhibitors (NRTIs) are important components of most antiretroviral combination treatment regimens. Using a large collection of clinical isolates, we characterized patterns of cross-resistance among all NRTIs. Drugs were grouped by the effect of the M184V mutation: susceptibility to group 1 drugs (zidovudine, stavudine, tenofovir, and adefovir) increased when M184V was present, whereas susceptibility to group 2 drugs (didanosine, zalcitabine, abacavir, and… CONTINUE READING